Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: luckydog88 who wrote (63231)	8/15/2025 11:14:52 PM
From: stockdoc77	4 Recommendations Read Replies (1) of 63276

Very disappointed to see Prasad brought back. The stock has bounced a bit but IMO still grossly oversold. They earned about 2 bucks/share last quarter alone. I see them earning 4-6 dollars over next 12 months. The stock should trade much higher, but I would be ecstatic if it just got to 50. I averaged down at 16 bucks. This roller coaster is even worse than IMMU. The only concerning issue is whether we see any more pt deaths. They had 2 in the first 1100 patients treated, both in older non-ambulatory kids which they have now stopped treating. They have a new immunosuppressive protocol using sirolimus which supposedly has prevented liver inflammation in the patients that have gotten it, they need to get enough data to go back to FDA and amend the treatment protocol to get the AA for non ambulatory reinstated.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next